NCT04373083View on ClinicalTrials.gov

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 15, 2020

Primary Completion Date

December 20, 2022

Study Completion Date

February 20, 2025

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Cemiplimab

Administered in 3-week intervals

RADIATION

Involved-site radiotherapy (IS-RT)

Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04373083 - Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter